Soligenix (SNGX) Gains from Investment Securities (2013 - 2016)
Soligenix's (SNGX) quarterly Gains from Investment Securities came in at -$432049.0 in Q4 2016, down 246.7% YoY from $294502.0 in Q1 2016, and down 345.07% on a QoQ basis from $176293.0 in Q3 2016.
Soligenix (SNGX) Gains from Investment Securities (2013 - 2016) Analysis & Trends
Soligenix (SNGX) has 4 years of Gains from Investment Securities data on file, last reported at -$432049.0 in Q4 2016.
- Quarterly Gains from Investment Securities fell 246.7% year-over-year to -$432049.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$1.5 million (down 228.24% YoY) and the FY2016 annual result came in at -$1.5 million, down 228.24% from the prior year.
- Gains from Investment Securities retreated to -$432049.0 in Q4 2016, from $176293.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.7 million in Q3 2013 to a low of -$4.0 million in Q3 2015.
- A 4-year average of $71098.5 and a median of -$432049.0 in 2016 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 360.18% in 2015, down 411.47% in 2015.
- Tracing SNGX's Gains from Investment Securities over 4 years: stood at $4.7 million in 2013, then sank by 177.45% to -$3.6 million in 2014, then jumped by 108.09% to $294502.0 in 2015, then sank by 246.7% to -$432049.0 in 2016.
- The last three Gains from Investment Securities figures came in at -$432049.0 (Q4 2016), $176293.0 (Q3 2016), and -$525328.0 (Q2 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -432,049.00 |
| Dec 31, 2016 | -432,049.00 |
| Sep 30, 2016 | 176,293.00 |
| Sep 30, 2016 | 176,293.00 |
| Jun 30, 2016 | -525,328.00 |
| Jun 30, 2016 | -525,328.00 |
| Mar 31, 2016 | -760,157.00 |
| Mar 31, 2016 | -760,157.00 |
| Dec 31, 2015 | 294,502.00 |
| Dec 31, 2015 | 294,502.00 |
| Sep 30, 2015 | -4.05 Mn |
| Sep 30, 2015 | -4.05 Mn |
| Jun 30, 2015 | 1.94 Mn |
| Jun 30, 2015 | 1.94 Mn |
| Mar 31, 2015 | 3.01 Mn |
| Mar 31, 2015 | 3.01 Mn |
| Dec 31, 2014 | -3.64 Mn |
| Dec 31, 2014 | -3.64 Mn |
| Sep 30, 2014 | -791,395.00 |
| Sep 30, 2014 | -791,395.00 |